|Calculated MW||12403 Da|
|Other Names||Migration and invasion enhancer 1, HBV X-transactivated gene 4 protein, HBV XAg-transactivated protein 4, Protein C35, MIEN1, C17orf37, RDX12, XTP4|
|Target/Specificity||A synthetic peptide corresponding to residues in human C35 was used as an immunogen.|
|Format||50 mM Tris-Glycine (pH 7.4), 0.15 M NaCl, 40% Glycerol, 0.01% sodium azide and 0.05% BSA.|
|Storage||Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.|
|Precautions||SRC Antibody is for research use only and not for use in diagnostic or therapeutic procedures.|
|Synonyms||C17orf37, RDX12, XTP4|
|Function||Increases cell migration by inducing filopodia formation at the leading edge of migrating cells. Plays a role in regulation of apoptosis, possibly through control of CASP3. May be involved in a redox-related process.|
|Cellular Location||Cytoplasm, cytosol. Cell membrane; Lipid- anchor; Cytoplasmic side. Note=Concentrates at the leading edge of migrating cells. Localizes outside membrane raft regions|
|Tissue Location||Among normal tissues, present only in Leydig cells. Strongly up-regulated in breast cancers and in brain cancer distant metastasis (at protein level). Up-regulated in prostate cancer cells and in the higher grades of prostate adenocarcinoma (at protein level).|
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
C35 (C17orf37, XTP4, ORB3) is a novel cancer marker encoded by a gene located on chromosome 17, adjacent to the Her2 oncogene. Similar to Her2, C35 is overexpressed in cancer tissues, in particular breast and prostate cancer tissues, but not in the normal homolog tissues. The functional role of C35 has not been identified. However, an analysis of predicted functional motifs of the gene product suggests that it may play a role in signal transduction and redox-related process (1). In prostate cancer, the downregulation of C35 leads to suppression of both Akt phospholyation and NF-kappa B activity. This suggests C35 might be involved in increasing the invasive potential of prostate cancer cells by NF-kappaB-mediated downstream target genes (2). Along with its tumor specific expression, C35 expression is persistent throughout tumor progression. Therefore, C35 is considered as an ideal biomarker for the diagnosis of both early-stage and late-stage cancer, and a possible anti-cancer therapeutic target (1, 2).
1. Evans EE et al., Mol Cancer Ther. 5(11):2919-30, 2006. 2. Dasgupta S, et al., Oncogene 28(32):2860-72, 2009.
If you have any additional inquiries please email technical services at email@example.com.